THC Prevents MDMA Neurotoxicity in Mice
Open Access
- 10 February 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (2), e9143
- https://doi.org/10.1371/journal.pone.0009143
Abstract
The majority of MDMA (ecstasy) recreational users also consume cannabis. Despite the rewarding effects that both drugs have, they induce several opposite pharmacological responses. MDMA causes hyperthermia, oxidative stress and neuronal damage, especially at warm ambient temperature. However, THC, the main psychoactive compound of cannabis, produces hypothermic, anti-inflammatory and antioxidant effects. Therefore, THC may have a neuroprotective effect against MDMA-induced neurotoxicity. Mice receiving a neurotoxic regimen of MDMA (20 mg/kg ×4) were pretreated with THC (3 mg/kg ×4) at room (21°C) and at warm (26°C) temperature, and body temperature, striatal glial activation and DA terminal loss were assessed. To find out the mechanisms by which THC may prevent MDMA hyperthermia and neurotoxicity, the same procedure was carried out in animals pretreated with the CB1 receptor antagonist AM251 and the CB2 receptor antagonist AM630, as well as in CB1, CB2 and CB1/CB2 deficient mice. THC prevented MDMA-induced-hyperthermia and glial activation in animals housed at both room and warm temperature. Surprisingly, MDMA-induced DA terminal loss was only observed in animals housed at warm but not at room temperature, and this neurotoxic effect was reversed by THC administration. However, THC did not prevent MDMA-induced hyperthermia, glial activation, and DA terminal loss in animals treated with the CB1 receptor antagonist AM251, neither in CB1 and CB1/CB2 knockout mice. On the other hand, THC prevented MDMA-induced hyperthermia and DA terminal loss, but only partially suppressed glial activation in animals treated with the CB2 cannabinoid antagonist and in CB2 knockout animals. Our results indicate that THC protects against MDMA neurotoxicity, and suggest that these neuroprotective actions are primarily mediated by the reduction of hyperthermia through the activation of CB1 receptor, although CB2 receptors may also contribute to attenuate neuroinflammation in this process.Keywords
This publication has 42 references indexed in Scilit:
- Crucial Role of CB2Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic PainJournal of Neuroscience, 2008
- CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and ReinforcementBiological Psychiatry, 2008
- CB2 receptors in the brain: role in central immune functionBritish Journal of Pharmacology, 2008
- The Dark Side of Ecstasy: Neuropsychiatric Symptoms after Exposure to 3,4‐MethylenedioxymethamphetamineBasic & Clinical Pharmacology & Toxicology, 2007
- Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational usersJournal of Neural Transmission, 2007
- MDMA‐induced neurotoxicity: long‐term effects on 5‐HT biosynthesis and the influence of ambient temperatureBritish Journal of Pharmacology, 2006
- Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptomsHuman Psychopharmacology: Clinical and Experimental, 2005
- Microglial activation is a pharmacologically specific marker for the neurotoxic amphetaminesNeuroscience Letters, 2004
- 3,4‐Methylenedioxymethamphetamine increases interleukin‐1β levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5‐HT depletionJournal of Neurochemistry, 2004
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993